glp 1 period GLP-1 RA prescription trends: January 2018 – September 2025 Started a GLP-1 and noticed

Currently, only two GLP-1s are approved by the FDA to treat obesity: Wegovy and Saxenda (liraglutide)

Miguens-Gomez 2021): A fast, neural-based release within 10-15 minutes of eating A slower, nutrient-based release ~60 minutes after eating, especially when nutrients reach the lower GI tract, Eating too quickly may short-circuit the gut-brain connection

doi: 10.3390/genes9030167

For instance, semaglutide users face a relative risk of 2.10 for constipation compared to placebo, while tirzepatide users have an even higher relative risk of 3.36

According to published reports, microdosing GLP-1 drugs is associated with side effects and complications, such as dizziness

Standard Medicare Part D prescription drug plans dont cover GLP-1 medications only for weight loss